In 2023, Andrew Hirsch earned $1.12M in total compensation at C4 Therapeutics, including $639.00K salary and $470.83K in stock. Most recently acquired 103,400 shares in Feb 2024. Currently holds stock worth $1.86M. Led C4 Therapeutics as CEO for 2 years.
Compensation History
Annual executive compensation data for Andrew Hirsch, including salary, bonuses, and stock awards.
Year
2023
Total Compensation
$1.12M
Salary
$639.00K
Bonus
$0.00
Other
$13.20K
Salary
$639.00KBoard Justification
The compensation program is designed to align executive interests with company performance and stockholder returns, focusing on long-term value creation.
Bonus
$0.00Board Justification
No bonus was awarded for 2023.
Other Compensation
$13.20KBoard Justification
This includes 401(k) matching contributions and other standard benefits.
Restricted Stock
Board Justification
81,600 RSUs were granted in 2023, vesting annually over four years.
Performance Metrics
The performance metrics for 2023 included achieving corporate objectives related to clinical development and financial performance.
Andrew Hirsch
Ex-CEO of C4 Therapeutics
Education
M.B.A. from the Tuck School at Dartmouth College; B.A. in Economics from the University of Pennsylvania
Field of Expertise
Finance & Banking - Finance
Sector of Economy
Healthcare
CEO of C4 Therapeutics for
2 years 11 months (Oct 2020 - Sep 2023)
Previous Experience
Chief Financial Officer at Agios Pharmaceuticals, Inc.; President and Chief Executive Officer of BIND Therapeutics, Inc.; Chief Financial Officer at Avila Therapeutics, Inc.; roles at Biogen Inc.
Other C4 Therapeutics CEOs
Holdings
Track Andrew Hirsch's stock holdings and portfolio value over time.
Insider Trading
Andrew Hirsch's recent stock transactions, purchases, and sales filed with the SEC.
103,400 shares
CCCC
Feb 14, 2024
Received
81,600 shares
CCCC
Feb 15, 2023
Received
$84.00K
CCCC at $8.40/share
Apr 12, 2022
Purchase
Rivals
Compare Andrew Hirsch with competitor CEOs and industry peers.